PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas

Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors

(2016) Gao Zhang et al.   JOURNAL OF CLINICAL INVESTIGATION

Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction

(2015) Gatien Moriceau et al.   CANCER CELL

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

(2015) Willy Hugo et al.   CELL

Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

(2015) C. Krepler et al.   CLINICAL CANCER RESEARCH

WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors

(2014) Jamie N. Anastas et al.   JOURNAL OF CLINICAL INVESTIGATION

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies

(2014) Lise Boussemart et al.   NATURE

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

(2014) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

(2014) Georgina V. Long et al.   Nature Communications

GSVA: gene set variation analysis for microarray and RNA-Seq data

(2013) Sonja Hänzelmann et al.   BMC BIOINFORMATICS

Pak1 Kinase Links ErbB2 to  -Catenin in Transformation of Breast Epithelial Cells

(2013) L. E. Arias-Romero et al.   CANCER RESEARCH

JNK regulates compliance-induced adherens junctions formation in epithelial cells and tissues

(2013) H. You et al.   JOURNAL OF CELL SCIENCE

P21-Activated Kinase 1 (PAK1) as a Therapeutic Target in BRAF Wild-Type Melanoma

(2013) Christy C. Ong et al.   JNCI-Journal of the National Cancer Institute

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

(2013) Cory M. Johannessen et al.   NATURE

Challenging resistance mechanisms to therapies for metastatic melanoma

(2013) Lucio Tentori et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

(2013) H. Shi et al.   Cancer Discovery

MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

(2013) N. Wagle et al.   Cancer Discovery

The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

(2013) E. M. Van Allen et al.   Cancer Discovery

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

α-Catenin inhibits glioma cell migration, invasion, and proliferation by suppression of β-catenin transactivation

(2010) Haitao Ji et al.   JOURNAL OF NEURO-ONCOLOGY

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth

(2010) B. W. Murray et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

(2009) David A. Barbie et al.   NATURE

Pak1 and Pak2 Mediate Tumor Cell Invasion through Distinct Signaling Mechanisms

(2008) S. J. Coniglio et al.   MOLECULAR AND CELLULAR BIOLOGY

Scaffolding function of PAK in the PDK1–Akt pathway

(2008) Maiko Higuchi et al.   NATURE CELL BIOLOGY